Jounce Therapeutics Net Tangible Assets

Jounce Therapeutics (JNCE) currently reports a net tangible assets of $180M as of December 2022. That compares with $220M in the prior-year period — down 18.2% year over year. Use the charts on this page to explore Jounce Therapeutics's net tangible assets history and peer comparisons.

Jounce Therapeutics's net tangible assets decreased from $220M to $180M — a 18.2% year-over-year decrease (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Jounce Therapeutics reported $180M in net tangible assets as of December 2022. That compares with $220M in the prior-year period — down 18.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $180M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Jounce Therapeutics, and consider following JNCE for alerts when major investors trade the stock.

Jounce Therapeutics is classified in the Healthcare sector. On net tangible assets, it currently shows $180M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing JNCE with unrelated industries.